Find Denifanstat manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Tvb-2640, 1399177-37-7, Denifanstat [inn], Denifanstat [usan], Fasn-in-2, 4gf95b2lza
Molecular Formula
C27H29N5O
Molecular Weight
439.6  g/mol
InChI Key
BBGOSBDSLYHMRA-UHFFFAOYSA-N
FDA UNII
4GF95B2LZA

Denifanstat
Denifanstat is an orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity. Upon administration, denifanstat binds to and blocks FASN, which prevents the synthesis of palmitate needed for tumor cell growth and survival. This leads to a reduction in cell signaling, an induction of tumor cell apoptosis and the inhibition of cell proliferation in susceptible tumor cells. FASN, an enzyme responsible for the de novo synthesis of palmitic acid, is overexpressed in tumor cells and plays a key role in tumor metabolism, lipid signaling, tumor cell survival and drug resistance; tumor cells are dependent on increased fatty acid production for their enhanced metabolic needs and rapid growth.
1 2D Structure

Denifanstat

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile
2.1.2 InChI
InChI=1S/C27H29N5O/c1-17-14-24(22-4-3-5-22)25(26-29-18(2)30-31-26)15-23(17)27(33)32-12-10-21(11-13-32)20-8-6-19(16-28)7-9-20/h6-9,14-15,21-22H,3-5,10-13H2,1-2H3,(H,29,30,31)
2.1.3 InChI Key
BBGOSBDSLYHMRA-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=CC(=C(C=C1C(=O)N2CCC(CC2)C3=CC=C(C=C3)C#N)C4=NNC(=N4)C)C5CCC5
2.2 Other Identifiers
2.2.1 UNII
4GF95B2LZA
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-1h-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile

2. Tvb-2640

2.3.2 Depositor-Supplied Synonyms

1. Tvb-2640

2. 1399177-37-7

3. Denifanstat [inn]

4. Denifanstat [usan]

5. Fasn-in-2

6. 4gf95b2lza

7. Tvb 2640 [who-dd]

8. 4-(1-(4-cyclobutyl-2-methyl-5-(3-methyl-1h-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile

9. 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4h-1,2,4-triazol-3- Yl)benzoyl)piperidin-4-yl)benzonitrile

10. 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4h-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile

11. Us8871790, 480

12. 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1h-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile

13. 4-{1-[4-cyclobutyl-2-methyl-5-(5-methyl-1h-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl}benzonitrile

14. Benzonitrile, 4-(1-(4-cyclobutyl-2-methyl-5-(3-methyl-1h-1,2,4-triazol-5-yl)benzoyl)-4-piperidinyl)-

15. Benzonitrile, 4-[1-[4-cyclobutyl-2-methyl-5-(3-methyl-1h-1,2,4-triazol-5-yl)benzoyl]-4-piperidinyl]-

16. Unii-4gf95b2lza

17. Asc-40

18. Chembl3661754

19. Schembl12488853

20. Bdbm137084

21. Bcp30428

22. Ex-a3643

23. S9714

24. Who 11784

25. Zinc150188638

26. Ac-35714

27. Hy-112829

28. Cs-0066310

29. Tvb2640; Tvb 2640;fasn-in-2

30. A937502

31. Us8871790, 152

2.4 Create Date
2012-10-30
3 Chemical and Physical Properties
Molecular Weight 439.6 g/mol
Molecular Formula C27H29N5O
XLogP35.3
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count4
Exact Mass439.23721057 g/mol
Monoisotopic Mass439.23721057 g/mol
Topological Polar Surface Area85.7 Ų
Heavy Atom Count33
Formal Charge0
Complexity728
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Drugs in Development

read-more
read-more

Details:

ASC40 (Denifanstat) is a FASN inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of acne vulgaris via oral tablet.


Lead Product(s): Denifanstat

Therapeutic Area: Dermatology Brand Name: ASC40

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 12, 2024

blank

01

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : ASC40 (Denifanstat) is a FASN inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of acne vulgaris via oral tablet.

Brand Name : ASC40

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 12, 2024

blank

Details:

TVB-264 (denifanstat) is a selective FASN inhibitor, which is under clinical development for the treatment of metabolic dysfunction-associated steatohepatitis/Non-alcoholic Steatohepatitis.


Lead Product(s): Denifanstat

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: TVB-2640

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 01, 2024

blank

02

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : TVB-264 (denifanstat) is a selective FASN inhibitor, which is under clinical development for the treatment of metabolic dysfunction-associated steatohepatitis/Non-alcoholic Steatohepatitis.

Brand Name : TVB-2640

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 01, 2024

blank

Details:

TVB-264 (denifanstat) is a selective FASN inhibitor, which is under clinical development for the treatment of metabolic dysfunction-associated steatohepatitis/Non-alcoholic Steatohepatitis.


Lead Product(s): Denifanstat

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: TVB-2640

Study Phase: Phase IProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 27, 2024

blank

03

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : TVB-264 (denifanstat) is a selective FASN inhibitor, which is under clinical development for the treatment of metabolic dysfunction-associated steatohepatitis/Non-alcoholic Steatohepatitis.

Brand Name : TVB-2640

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 27, 2024

blank

Details:

TVB-2640 (denifanstat) is an orally bioavailable fatty acid synthase (FASN) inhibitor. It is being evaluated in phase 2 clinical trials for the treatment of Nonalcoholic Fatty Liver Disease.


Lead Product(s): Denifanstat

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: TVB-2640

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 23, 2024

blank

04

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : TVB-2640 (denifanstat) is an orally bioavailable fatty acid synthase (FASN) inhibitor. It is being evaluated in phase 2 clinical trials for the treatment of Nonalcoholic Fatty Liver Disease.

Brand Name : TVB-2640

Molecule Type : Small molecule

Upfront Cash : Not Applicable

January 23, 2024

blank

Details:

TVB-2640 (denifanstat) is an oral, selective FASN inhibitor which is under phase 2 clinical development for the treatment of non-alcoholic steatohepatitis patients with stage 2 or stage 3 fibrosis.


Lead Product(s): Denifanstat

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: TVB-2640

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2024

blank

05

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : TVB-2640 (denifanstat) is an oral, selective FASN inhibitor which is under phase 2 clinical development for the treatment of non-alcoholic steatohepatitis patients with stage 2 or stage 3 fibrosis.

Brand Name : TVB-2640

Molecule Type : Small molecule

Upfront Cash : Not Applicable

January 22, 2024

blank

Details:

ASC40 (Denifanstat) is a FASN inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of acne vulgaris via oral tablet.


Lead Product(s): Denifanstat

Therapeutic Area: Dermatology Brand Name: ASC40

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 05, 2023

blank

06

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : ASC40 (Denifanstat) is a FASN inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of acne vulgaris via oral tablet.

Brand Name : ASC40

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 05, 2023

blank

Details:

ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated in combined with bevacizumab for the treatment of recurrent glioblastoma.


Lead Product(s): Denifanstat,Bevacizumab

Therapeutic Area: Oncology Brand Name: ASC40

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Ascletis Pharma

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 27, 2023

blank

07

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated in combined with bevacizumab for the treatment of recurrent glioblastoma.

Brand Name : ASC40

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 27, 2023

blank

Details:

ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated for the treatment of mild-moderate acne vulgaris.


Lead Product(s): Denifanstat

Therapeutic Area: Dermatology Brand Name: ASC40

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 02, 2023

blank

08

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated for the treatment of mild-moderate acne vulgaris.

Brand Name : ASC40

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 02, 2023

blank

Details:

ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN), a key enzyme which regulates DNL. Human sebum production requires de novo lipogenesis, which is increased in acne and can be suppressed by the FASN inhibitor ASC40.


Lead Product(s): Denifanstat

Therapeutic Area: Dermatology Brand Name: ASC40

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 30, 2022

blank

09

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN), a key enzyme which regulates DNL. Human sebum production requires de novo lipogenesis, which is increased in acne and can be suppressed by the FASN inhibito...

Brand Name : ASC40

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 30, 2022

blank

Details:

Denifanstat (TVB-2640) is an oral, selective, first-in-class fatty acid synthase inhibitor that directly targets the primary drivers of NASH by reducing excess liver fat (steatosis), decreasing inflammation and blunting fibrosis.


Lead Product(s): Denifanstat

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: TVB-2640

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 03, 2022

blank

10

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : Denifanstat (TVB-2640) is an oral, selective, first-in-class fatty acid synthase inhibitor that directly targets the primary drivers of NASH by reducing excess liver fat (steatosis), decreasing inflammation and blunting fibrosis.

Brand Name : TVB-2640

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 03, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Denifanstat Manufacturers

A Denifanstat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Denifanstat, including repackagers and relabelers. The FDA regulates Denifanstat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Denifanstat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Denifanstat Suppliers

A Denifanstat supplier is an individual or a company that provides Denifanstat active pharmaceutical ingredient (API) or Denifanstat finished formulations upon request. The Denifanstat suppliers may include Denifanstat API manufacturers, exporters, distributors and traders.

Denifanstat GMP

Denifanstat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Denifanstat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Denifanstat GMP manufacturer or Denifanstat GMP API supplier for your needs.

Denifanstat CoA

A Denifanstat CoA (Certificate of Analysis) is a formal document that attests to Denifanstat's compliance with Denifanstat specifications and serves as a tool for batch-level quality control.

Denifanstat CoA mostly includes findings from lab analyses of a specific batch. For each Denifanstat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Denifanstat may be tested according to a variety of international standards, such as European Pharmacopoeia (Denifanstat EP), Denifanstat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Denifanstat USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty